TRN 004
Alternative Names: TRN-004Latest Information Update: 05 Feb 2021
At a glance
- Originator Turn Biotechnologies
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 03 Feb 2021 Turn Biotechnologies in-licenses artificial niche (AN) technology from Stanford University
- 03 Feb 2021 Turn Biotechnologies has patents pending for artificial niche (AN) technology in major-market nations on six continents
- 12 Jan 2021 TRN 004 is available for licensing as of 12 Jan 2021. https://www.turn.bio/opportunities